myelotoxic

myelotoxic

 [mi´ĕ-lo-tok″sik]
1. destructive to bone marrow.
3. arising from diseased bone marrow.

my·e·lo·tox·ic

(mī'ĕ-lō-tok'sik),
1. Inhibitory, depressant, or destructive to one or more of the components of bone marrow.
2. Pertaining to, derived from, or manifesting the features of diseased bone marrow.

myelotoxic

/my·elo·tox·ic/ (mi´ĕ-lo-tok″sik)
1. destructive to bone marrow.
3. arising from diseased bone marrow.

my·e·lo·tox·ic

(mī'ĕ-lō-tok'sik)
1. Inhibitory, depressant, or destructive to one or more of the components of bone marrow.
2. Pertaining to, derived from, or manifesting the features of diseased bone marrow.
References in periodicals archive ?
The randomised, multi-centre, double-blind, placebo-controlled phase III study investigated the safety and efficacy of a once-per-cycle dose of F-627 in women with stage II-IV breast cancer who are receiving myelotoxic TA chemotherapy treatment (Taxotere (docetaxel + Adriamycin (doxorubicin)), with participants randomised 2:1.
However, it is important to highlight that some detergents contain benzene, which is considered by the International Agency for Research on Cancer to be a myelotoxic agent, that is, highly toxic and carcinogenic to bone marrow (7).
The etiology of thrombocytopenia in liver disease include portal hypertension (through hypersplenism), antibody-mediated platelet destruction (mainly in viral hepatitis), decreased thrombopoietin production by diseased liver and myelotoxic effects of alcohol and hepatitis virus6.
In 2003, Giannini et al, [9] first of all, introduced the use of the PC/SD ratio as a tool to predict EV to link thrombocytopenia to splenomegaly to introduce a variable that takes into consideration that thrombocytopenia is mainly due to hypersplenism secondary to portal hypertension though there are many other factors also for thrombocytopenia in cirrhosis other than portal hypertension including shortened mean platelet lifetime, decreased thrombopoietin (TPO) production or the myelotoxic effects of hepatitis C virus.
In vitro myelotoxic effects of cypermethrin and mancozeb on human hematopoietic progenitor cells.
Treatment with myelotoxic chemotherapy frequently leads to neutropenia.
7, 12] The myelotoxic effects in association with liposomal doxorubicin include leukopenia, neutropenia, thrombocytopenia, and febrile neutropenia.
15) In the present study, severe and moderate neutropenia were observed in a few cases, and the majority of them had been treated with other myelotoxic drugs associated with toxoplasmosis treatment, although all adverse effects were reversible with increased folinic acid doses and temporary interruption of the treatment.
It was chosen because it causes less nephrotoxicity neurotoxicity ototoxicity nausea and vomiting than cisplatin and is more myelotoxic.
Contributing factors might be using chemicals, viral infections, and myelotoxic agents.
27,31,32) However, it is also contraindicated in patients with previous episodes of myelo-suppression (bone marrow suppression), those on myelotoxic (bone marrow suppressive) drugs (typically used in chemotherapy), or patients with a history of allergic reaction to chloramphenicol.
The frequency of pattern of disease causing them varies in different population groups and this has been attributed to differences in methodology and stringency of diagnostic criteria, geographical area, period of observation, genetic differences, nutritional status, prevalence of infection and varying exposure to myelotoxic drugs among others.